Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with ⁸⁹Zr-labelled CI-8993.

ABSTRACT:

Background

CI-8993 is a fully human IgG1κ monoclonal antibody (mAb) that binds specifically to immune checkpoint molecule VISTA (V-domain Ig suppressor of T-cell activation). Phase I safety has been established in patients with advanced cancer (NCT02671955). To determine the pharmacokinetics and biodistribution of CI-8993 in patients, we aimed to develop ⁸⁹Zr-labelled CI-8993 and validate PET imaging and quantitation in preclinical models prior to a planned human bioimaging trial.

Methods

CI-8993 and human isotype IgG1 control were conjugated to the metal ion chelator p-isothiocyanatobenzyl-desferrioxamine (Df). Quality of conjugates were assessed by SE-HPLC, SDS-PAGE, and FACS. After radiolabelling with zirconium-89 (⁸⁹Zr), radioconjugates were assesse

SUBMITTER: Burvenich IJG 

PROVIDER: S-EPMC11527895 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature